Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia
This study is for children with achondroplasia, a condition that affects how bones grow, leading to shorter stature. We are testing a new medicine called BMN 333 against an existing treatment, Vosoritide (also known as Voxzogo). The main goal is to see how effectively BMN 333 helps children grow and if it is safe to use. This research is divided into two main parts. The first part helps decide the best dose of BMN 333, and the second part will compare this chosen dose directly with Vosoritide. Children taking part must not have received other growth-promoting treatments for their achondroplasia before joining the study.
نظرة سريعة
ما هو موضوع هذه الدراسة؟
This study is for children who have achondroplasia, a condition often called dwarfism, which affects bone growth and leads to shorter arms and legs. While there are some treatments available, scientists are always looking for new and better ways to help children with this condition.
This research is testing a new medicine, called BMN 333, against an existing treatment, Vosoritide (you might know it as Voxzogo). The main purpose is to see if BMN 333 can help children grow more effectively than Vosoritide and to make sure it's safe to use. The study is split into two main sections: first, researchers will find the best dose of BMN 333 to use, and then they will compare that dose directly with Vosoritide.
Taking part in this study could help doctors understand more about treating achondroplasia. Your child would be carefully monitored throughout the study by a team of medical professionals. The information learned from participants could help future generations of children with achondroplasia.
النقاط الرئيسية
- Aims to compare a new medicine (BMN 333) with an existing one (Vosoritide) for achondroplasia.
- For children aged 2-17 years with achondroplasia who haven't had prior growth treatments.
- Treatment involves weekly (for BMN 333) or daily (for Vosoritide) injections for 52 weeks.
- Study duration is up to 14 months, including regular clinic visits and follow-up.
- The study seeks to understand effects on growth and safety.
من قد يكون مؤهلاً؟
This study is open to boys and girls who have achondroplasia. They need to be between 2 and 17 years old. It's really important that their achondroplasia has been confirmed by a genetic test, and that their growth plates (the areas where bones grow) are still open.
Children generally need to be able to walk and stand on their own without help. They also shouldn't have any other conditions that cause short stature. If they have certain medical conditions like untreated thyroid problems, poorly controlled diabetes, or serious heart or kidney issues, they might not be able to join.
Crucially, children cannot have received Vosoritide or any other medicine, treatment, or medical device specifically for achondroplasia or short stature before. They also shouldn't have had certain other growth-related treatments in the 6 months leading up to the study, like growth hormone or certain steroids.
هل يمكن أن تناسبك هذه الدراسة؟
أجب عن هذه الأسئلة السريعة لترى ما إذا كنت مؤهلاً. هذا دليل فقط - الفريق البحثي هو الذي يتخذ القرار النهائي.
- هل عمر طفلك بين 2 و 17 سنة؟
- Does your child have achondroplasia confirmed by a genetic test?
- Can your child walk and stand on their own?
- Has your child *never* received any other drugs specifically for achondroplasia before (like Vosoritide or growth hormone in the last 6 months)?
- Does your child *not* have other serious medical conditions like untreated thyroid issues or significant heart problems?
ماذا يتضمن المشاركة؟
If your child joins this study, they will receive either BMN 333 or Vosoritide. BMN 333 is given once a week, and Vosoritide is given once a day, both as an injection. The treatment part of the study will last for 52 weeks (about one year).
Throughout the study, your child will have regular visits to the clinic for check-ups, assessments, and to check how they are growing. The medical team will also look for any side effects. The total time active in the study, from your first visit to the final check-up after treatment, will be up to 61 weeks (around 14 months).
There will be follow-up visits after the treatment finishes to monitor your child's health and safety.
المخاطر والفوائد المحتملة
المواقع (28)
- مستشفى الأطفال UCSF Benioff في أوكلاندالرمز البريدي المؤكدأوكلاند، الولايات المتحدة· التوظيف
- Nemours Children's Healthالرمز البريدي المؤكدويلمنجتون، الولايات المتحدة· لم يبدأ التوظيف بعد
- مستشفى آن وروبرت إتش. لوري للأطفال في شيكاغوالرمز البريدي المؤكدشيكاغو، الولايات المتحدة· التوظيف
- Johns Hopkins Medicineالرمز البريدي المؤكدبالتيمور، الولايات المتحدة· التوظيف
- مركز سينسيناتي الطبي للأطفالالرمز البريدي المؤكدسينسيناتي، الولايات المتحدة· التوظيف
- مستشفى الأطفال في فيلادلفياالرمز البريدي المؤكدفيلادلفيا، الولايات المتحدة· التوظيف
- Texas Children's Hospitalالرمز البريدي المؤكددالاس، الولايات المتحدة· التوظيف
- Texas Children Hospital, Baylor College of Medicineالرمز البريدي المؤكدهيوستن، الولايات المتحدة· التوظيف
- Consano Clinical Research, LLCالرمز البريدي المؤكدسان أنطونيو، الولايات المتحدة· التوظيف
- Murdoch Children's Research Instituteالرمز البريدي المؤكدباركفيل، أستراليا· التوظيف
- مركز الصحة بجامعة ماكجيلالرمز البريدي المؤكدكيبك، كندا· التوظيف
- Universite de Montreal - Centre Hospitalier Universitaire Sainte-Justineالرمز البريدي المؤكدمونتريال، كندا· التوظيف
أسئلة شائعة
What is achondroplasia?
Achondroplasia is a genetic condition that affects how bones grow, leading to shorter arms, legs, and a normal-sized torso. It's the most common type of dwarfism.
What is the difference between BMN 333 and Vosoritide?
BMN 333 is a new medicine being tested in this study. Vosoritide (Voxzogo) is an existing medicine approved for treating achondroplasia. This study compares them.
هل سيحصل طفلي بالتأكيد على الدواء الجديد؟
Participants will be randomly chosen to receive either BMN 333 or Vosoritide. Neither you nor the study doctor will choose which treatment your child receives.
كم ستستغرق مدة العلاج؟
The treatment period for this study is 52 weeks, which is about one year, with follow-up visits afterwards.
What do the 'Phase 2' and 'Phase 3' parts mean?
Clinical trials are done in phases. Phase 2 checks for the right dose and initial safety, and Phase 3 compares the new treatment against an existing one in a larger group of people to confirm its effectiveness and safety.
كيفية معرفة المزيد
أخصائي التجارب
تحدث دائمًا إلى طبيبك العام أو الأخصائي قبل اتخاذ قرار بالمشاركة في دراسة.
هل أنت مهتم بالمشاركة؟
نقاش
مناقشة المجتمع
مدعوم من منتدانا في community.patient.info. يرجى التحلي بالاحترام — هذه ليست نصيحة طبية.